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PARTICLE COMPOSITIONS WITH A 
PRE -SELECTED CELL INTERNALIZATION 
MODE 
STATEMENT FOR FEDERALLY FUNDED 
RESEARCH 
This invention was made with government support under 
Grant No. W311`4Q-07-1-0008, awarded by Defense 
Advanced Research Projects Agency (DARPA); and under 
Grant No. NNJ06HE06A, awarded by NASA. The U.S. gov-
ernment has certain rights in the invention. 
FIELD 
The inventions relate generally to micro and nanosized 
particle compositions and their applications and, more par-
ticularly, to micro and nanosized particle compositions hav-
ing a particular pre-selected cell internalization mode. 
BACKGROUND 
Endocytosis is a general term defining processes, by which 
a cell can import and/or export selected extracellular species, 
such as molecules, viruses, particles and microorganisms and 
target them to specific organelles within a cytoplasm. 
Endocytosis can occur through a variety of pathways includ-
ing clathrin-mediated and caveole-mediated endocytosis; 
phagocytosis; clathrin- and caveole-independent endocyto-
sis. A particular endocytosis pathway may depend on the size 
and nature of the extracellular cargo, see e.g. Conner S. D. and 
S. L. Schmid. 2003. Nature 422: 37-44. For instance, caveole-
mediated endocytosis is assisted by the activation of caveole, 
plasma membrane invaginations, with a characteristic size of 
50-60 mu; clathrin-mediated endocytosis requires the con-
centration of transmembrane receptors and their bound 
ligands on the plasma membrane leading to the formation of 
vesicular cages with a characteristic size up to few hundreds 
microns (100-500 mu); phagocytosis involves specific cell-
surface receptors and signaling cascades with the formation 
of cell membrane protrusions that eventually envelope the 
external micrometer cargo (>1 µm). Clathrin- and caveole-
independent endocytosis can be associated with the forma-
tion of invaginating vesicles smaller than 100 mu. 
Particle endocytosis can be of fundamental importance in 
several fields, such as virology, drug and gene delivery and in 
nanotoxicology, see e.g. Marsh M. and A. Helenius. 2006. 
Cell 124:729-40; Vasir J. K., and V. Labhasetwar. 2006. 
Expert Opin. Drug Deliv. 3:325-344; Oberdorster G., E. 
Oberdorster, J. Oberdorster. 2005. 113:823-39. 
For nanosized particles, both natural, such as enveloped 
viruses, or artificial, such as biomimetic particulates, the most 
effective internalization mechanism can be a receptor-medi-
ated endocytosis, in which molecules (ligands) distributed 
over the particle surface bind to countermolecules (receptors) 
expressed over the cell membrane, which can eventually bend 
to invaginate the foreign cargo, see e.g. Marsh M. and A. 
Helenius. 2006. Cell 124:729-40; Smith A. E., A. Helenius. 
2004. Science 304:237-42. These receptors can be collected 
at the site of invagination by surface diffusion, without which 
endocytosis would not occur or would occur over a much 
longer time scale. 
2 
mode, which comprises a) selecting a cell having surface 
receptors; and b) obtaining particles that have i) surface moi-
eties, that have an affinity for or are capable of binding to the 
receptors, and ii) a shape, wherein a surface distribution of the 
5 surface moieties and the shape are effective for the pre-se-
lected cell internalization mode for the selected cell. 
Another embodiment is a method of treating or monitoring 
a physiological condition comprising administering to a sub- 
10 
ject in need thereof an effective amount of a particle compo-
sition having a pre-selected cell internalization mode. 
Yet another embodiment is a particle composition having a 
pre-selected cell internalization mode. 
15 	
DRAWINGS 
FIG.1 schematically depicts a particle that has an elliptical 
cross-section. The particle has ligand molecules on its surface 
that can interact with receptor molecules on a surface of cell's 
20 membrane. 
FIG. 2 illustrates evolution of the elliptical cylindrical par-
ticle presenting the half-wrapping time 0.5ti w and the wrap-
ping length ratio x_,,/R, as a function of the aspect ratio F, 
ranging from 0.9 to 4, for Rz fixed at 50 mu. 
25 	 FIG. 3 presents a graph of F_,,, which is a value of E for a 
fixed Rz corresponding to the minimum for the half-wrapping 
time, as a function of R2 . FIG. 3 also presents a graph of the 
half-wrapping time for F_,, „ as a function of R2 . 
FIG. 4 illustrates evolution of the elliptical cylindrical par- 
30 ticle presenting the half-wrapping time 0.5ti w and the wrap-
ping length ratio x_,,/R, as a function of the aspect ratio F, 
ranging from 0.9 to 4, for a fixed volume (R,-50 mu). 
DETAILED DESCRIPTION 
35 
Related Documents 
The following research articles and patent documents, 
40 which are all incorporated herein by reference in their 
entirety, may be useful for understanding the present inven-
tions: 
1) PCT publication no. WO 2007/120248 published Oct. 25, 
2007; 
45 2) PCT publication no. WO 2008/041970 published Apr. 10, 
2008; 
3) PCT publication no. WO 2008/021908 published Feb. 21, 
2008; 
4) US Patent Application Publication no. 2008/0102030 pub-
50 	 lished May 1, 2008; 
5) US Patent Application Publication no. 2003/0114366; 
6) U.S. patent application Ser. No. 12/034,259 filed Feb. 20, 
2008; 
7) U.S. patent application Ser. No. 12/110,515 filed Apr. 28, 
55 	 2008; 
8) Tasciotti et al., Nature Nanotechnology, vol. 3, 151-158, 
2008; 
9) Decuzzi and Ferrari, Biomaterials 28, 2007, 2915-2922; 
10) Decuzzi and Ferrari, Biophysical Journal, 94, 2008, 
60 	 3790-3797. 
Definitions 
SUMMARY 	 Unless otherwise specified "a" or "an" means one or more. 
65 	 Unless otherwise specified the terms "endocytosis" and 
	
One embodiment provides a method of formulating a par- 	 "endocytotic" mean receptor mediated endocytosis and 
	
ticle composition having a pre-selected cell internalization 	 receptor mediated endocytotic respectively. 
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4 
"Microparticle" refers to a particle having a maximum 
dimension from 1 micrometer to 1000 micrometers, or, in 
some embodiments from 1 micron to 100 microns as speci-
fied. 
"Nanoparticle" refers to a particle having a maximum 
dimension of less than 1 micron. 
"Phagocytosis" refers to an uptake of large (characteristic 
size of more than 2 microns) particles by specialized phago-
cyte cells, which include macrophages, monocytes and neu-
trophils. Phagocytosis involves the formation of protrusions 
in the cell membrane that eventually envelope the external 
particle. 
"Receptor mediated endocytosis" or RME refers to an 
internalization by a cell of aparticle, which has moieties, such 
as ligands, distributed over its surface, which can bind to 
countermoieties (receptors) expressed over the cell's mem-
brane. RME involves bending of the cell's membrane, which 
results in a full wrapping of the particle by the membrane and 
eventual internalization of the particle by the cell. Particles 
that are internalized via RME can have smaller characteristic 
size than particles that undergo internalization via phagocy-
tosis. RME is not limited to phagocyte cells. 
"Biodegradable" refers to a material that can dissolve or 
degrade in a physiological medium or a biocompatible poly-
meric material that can be degraded under physiological con-
ditions by physiological enzymes and/or chemical condi-
tions. 
Disclosure 
The present inventors recognized an importance of a par-
ticle shape for a receptor mediated endocytosis. Accordingly, 
the present invention provides a method of formulating a 
particle composition with a pre-selected cell internalization 
mode, which can involve selecting a target cell and obtaining 
particles that have on their surfaces surface moieties, that 
have affinity for or are capable of binding to surface receptors 
of the surface of the target cell. The surface distribution of the 
surface moieties on the particles and a shape of the particles 
are such that they are effective for the pre-selected cell inter-
nalization mode for the selected cell. 
The pre-selected cell internalization mode may be selected 
from an "endocytosis" or "no-endocytosis" mode. "Endocy-
tosis" refers to a mode, when a particle can be fully wrapped 
by the cell's membrane via a receptor mediated endocytosis 
and eventually internalized, "no-endocytosis" refers to a 
mode, when the particle can be at most partially wrapped by 
the cell's membrane. 
In some embodiments, the pre-selected cell internalization 
mode may a frustrated or partial endocytosis. "Frustrated 
endocytosis" refers to a mode, when the particle gets only 
partially wrapped by the cell's membrane and does not get 
internalized by the cell. 
The particles with a pre-selected cell internalization mode 
may be used for treating and/or monitoring a physiological 
condition. In such a case, one can select a target site, which is 
affected with the physiological condition and has cells of 
which have surface receptors on its surface, in a body of a 
subject, such as a mammal, preferably a human, and admin-
istering to the subject an effective amount of a composition 
that comprises particles with a pre-selected internalization 
mode for the cells of the target site. The physiological condi-
tion can be for example a disease, such as cancer or an 
inflammation. 
In general, the selected cell may be any type of cell that has 
surface receptors on its surface. In many embodiments, the 
selected cells can be a mammal cell, such as a human cell. 
A particular selected internalization mode may depend on 
the application intended for the particles. For example, the 
endocytosis mode may be preferred when the particle con-
tains a cargo, such as an imaging or a therapeutic agent, which 
5 is desired to be delivered inside the cell. On the other hand, no 
endocytosis or frustrated endocytosis modes may be pre-
ferred when the particle contains a cargo, which is not 
intended for delivery inside the cell. One example of such 
situation can be a multistage delivery vehicle disclosed in 
10 PCT publication WO 2008/021908, where a first stage par-
ticle of the vehicle, which contains inside second stage par-
ticles, is intended to recognize and adhere to a target site in 
endothelium, without being internalized by the endothelial 
15 cells. After adherence, the first stage particle can release the 
second stage particles. 
In many embodiments, the selected cell can be a non-
phagocyte cell, i.e. a cell that cannot perform phagocytosis. 
Examples of phagocyte cells, i.e. cells that perform phagocy- 
20 tosis include neutrophills, monocytes and macrophages. 
In some embodiments, the selected cell may be an endot-
helial cell, such as an endothelial vasculature cell, and the 
target site may be a vasculature site, such as a coopted vas-
culature, an angiotensic vasculature or a renormalized vascu- 
25 lature. For cells of coopted vasculature, the surface receptors 
may be angiopoietin 2 receptors; for cells of angiogenic vas-
culature, the surface receptors may be vascular endothelial 
growth factors (VEGF), basic fibroblast growth factors or 
endothelial markers such as 04 3 integrins; for cells of renor- 
30 malized vasculature, the surface receptors may be carcino-
embionic-related cell adhesion molecules 1 (CEACAMI), 
endothelin-B receptor (ET-B), vascular endothelial growth 
factor inhibitors gravin/AKAP12, scaffolding proteins for 
protein kinase A and protein kinase C. 
35 	 The surface moieties of the particle's surface can be com- 
plimentary to the receptors on the selected cell's surface. The 
surface moieties maybe, for example, antibodies, aptamers or 
ligands with affinity for or capable of binding to the receptors 
on the selected cell's membrane surface. In some embodi- 
40 ments, the surface moieties may include specific moieties to 
the receptors on the selected cell's membrane surface. In 
some embodiments, the surface moieties may include non-
specific moieties to the receptors on the selected cell's mem-
brane surface. Yet in other embodiments, the surface moieties 
45 may include both specific and non-specific moieties. 
Particles with a pre-selected internalization mode may be a 
part of a composition that can also include particles without 
the pre-selected internalization mode. The particles with the 
pre-selected internalization mode may constitute at least 10% 
50 or at least 25% or at least 50% or at least 75% or at least 90% 
by number of the total number of particles in the composition. 
In many embodiments, the particle can be a non-spherical 
particle. In some embodiments, the particle can be a particle 
with a circular cross section. In some embodiments, the par- 
55 ticle can be an ellipsoidal particle. Yet in other embodiments, 
the particle can be a cylindrical particle with an elliptical 
cross section in a direction perpendicular to the axis of the 
cylinder. 
In some embodiments, the particle's largest characteristic 
60 size, such as a length of its major axis for a particle with an 
elliptical cross section, canbe less than 2 microns, or less than 
1 micron or less than 800 nm or from 5 nm to 500 nm or from 
5 nm to 800 nm from 5 nm to 1 micron or from 10 nm to 1 
micron or from 10 nm to 800 nm or from 10 nm to 500 nm or 
65 from 20 nm to 1 micron or from 20 nm to 800 nm or from 20 
nm to 500 nm or from 50 nm to 1 micron or from 50 nm to 800 
nm or from 50 nm to 500 nm. 
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Preferably, the particle's largest characteristic size is sub-
stantially smaller than a characteristic size of the selected cell. 
Theparticle's largest characteristic size can be at least  times 
smaller or at least 5 times smaller or at least 10 times smaller 
or at least 20 times smaller or at least 30 times smaller or at 5 
least 50 times smaller or at least 100 times smaller or at least 
200 times smaller or at least 300 times smaller or at least 500 
times smaller or at least 100 times smaller than the charac-
teristic size of the selected cell. A characteristic size of the 
selected cell may vary from about 5 microns to about 40 10 
microns or from about 10 microns to about 30 microns. 
In some embodiments, the obtained particles may be par-
ticles that have a convex subsurface with a local curvature and 
a local surface density of the moieties, such as ligands, that 
are effective for internalization of the particles via a receptor 15 
mediated endocytosis, which means that the local curvature K 
is smaller than a maximum endocytosis curvature K_ for the 
local surface density of the moieties. Maximum endocytosis 
curvature can depend on a binding energy between moieties 
on the surface of the particle and receptors on the surface of 20 
the selected cell's membrane, a bending energy factor of the 
selected cell's membrane and surface densities of the moi-
eties of the particle and of the receptors on the selected cell's 
membrane. Methods of evaluating maximum endocytosis 
curvature are disclosed below. 25 
In some embodiments, the local surface density of the 
moieties at the convex surface may be greater than a surface 
density of the moieties at other parts of the surface of the 
particle, thus, making a surface distribution of the surface 
moieties on the surface of the particle non-uniform. 30 
For particles with an elliptical cross section, obtaining 
particles with a pre-selected cell internalization mode may 
involve obtaining particles that have an aspect ratio corre-
sponding to the selected mode. 
For example, FIG. 1 illustrates a elliptical cross section of 35 
an elliptical cylindrical particle that interacts with a mem-
brane via specific ligand receptor bonds. A surface density of 
the ligands on the surface of the particle is rn , while the 
surface density of the receptors on a surface of the cell's 
membrane is m, 40 
The elliptical cross section can be characterized R 1 and Rz , 
which are semi-lengths of the axes of the ellipse. An aspect 
ratio of the ellipse, which can be defined as F=R,/R 2 . The 
cross sectional area of the particle isA=7iR 1 R2 7iFR22-7iRs2 , 
where RS is a radius of a particle with a circular cross-section 45 
that has the same are as the elliptical particle. 
The geometry of the particle can be fully defined by a 
number of pairs of parameters such R 1 and R2 ; F and R 1 ; F 
and R21  F and RS or F and V, where V is the volume of the 
particle. 50 
In a case, when the geometry of the particle is defined 
through F and R2, a shape parameter determining a pre-
selected internalization mode can be an aspect ratio F for a 
particular R2 . 
The particle with an elliptical cross section can be in a 55 
"no-endocytosis" mode if the aspect ratio of the particle for a 
particular semilength of a minor axis is less than a first critical 
value F'=(R2 Km ,,)-112, where K_ is a maximum endocytosis 
curvature, which is defined below. 
The particle can be in a frustrated endocytosis mode if the 60 
aspect ratio of the particle for a particular semilength of its 
minor axis is no greater than a second critical value, 
F—R Km_ 2 
The particle can be in an endocytosis mode if the aspect 
ratio of the particle for a particular semilength of its minor 65 
axis is greater than the first critical value, F', and less than the 
second critical value, F".  
6 
The maximum endocytosis curvature K_ can be defined 
as an inverse minimum endocytotic radius calculated for the 
selected cell for a spherical particle or a particle with a circu-
lar cross section that has the same ligands on its surface as the 
non-spherical particle. 
The minimum endocytotic radius and thus the maximum 
endocytotic curvature can be evaluated using the formula (1) 
Fm
B m' m,K_,— R.i,,_ C--+log—+1 
 m 1 m 1 
In the equation above, C is the ligand-receptor binding 
energy relative to kBT, where kB is the Bolzmann's constant 
and T is a temperature of the cell or the target site expressed 
in Kelvins (absolute temperature). C depends on a particular 
ligand-receptor pair. In particular, C= log[Kd2D] Kd2D  is an 
equilibrium dissociation constant for the ligand-receptor 
interacting at the cell/particle interface. Kd2D  can be esti-
mated from the following relation Kd'  Kd/h, where Kd i s an 
equilibrium dissociation constant for the same ligand-recep-
tor pair determined, for example, experimentally in solution 
and h is a thickness of a confinement region, to which the 
ligand-receptor sites are restricted. In many cases, h can be 
equal approximately to 10 mu. 
B is a bending energy factor of the cell's membrane, which 
can be determined as detailed in Hochmuth, R. M., J. Bio-
mech., 33:15-22, 2000. 
m,,, which is an average surface density on the receptors, 
when the particle is not interacting with the cell, can be 
determined using methods known to those of ordinary skill in 
the art. For example, one can determine m,, in vivo by using 
radiolabeled monoclonal antibodies complimentary to the 
receptors as detailed for intercellular adhesion molecule 1 
receptors in Panes J., et al. Am. J. Physiol. 1995; 269(6Pt2): 
H1955-64. Alternatively, m,, can be determined using fluores-
cently labeled monoclonal antibodies complementary to the 
receptors. Such fluorescently labeled monoclonal antibodies 
can be antibodies labeled with phycoerythrin disclosed in 
U.S. Pat. No. 4,520,110. 
m, is a local surface density of ligands rn, which can be 
varied by controlling surface functionalization conditions for 
the particle and/or by varying a size of the ligand molecule. 
The actual surface density of ligands on the particle can be 
verified experimentally using citofluometry or radiolabeled 
countermolecules in radioassays. 
For a particle with a uniform surface distribution of 
ligands, the local surface density and the average surface 
density can be the same. 
In certain embodiments, the minimum endocytotic radius 
and thus the maximum endocytotic curvature can be evalu-
ated as disclosed in U.S. patent application Ser. No. 12/034, 
259 "Endocytotic particles" filed Feb. 20, 2008, which is 
incorporated herein by reference in its entirety. 
FIG. 2 illustrates evolution of the elliptical cylindrical par-
ticle presenting the half-wrapping time 0.5ti w and the wrap-
ping length ratio x_,,/R1 as a function of the aspect ratio F, 
ranging from 0.9 to 4, for R 2-50 nm evaluated using a theo-
retical model disclosed in Decuzzi and Ferrari, Biophysical 
Journal, 94, 2008, 3790-3797, which is incorporated herein 
by reference in its entirety. x m ,, is a projection of the parti-
cle's wrapping length over the x-axis in FIG. 1. For x m ,,/ 
R 1=1 complete wrapping occurs at time tiw . In FIG. 2, for 
F<F'',,,which about 0.9 in this case, wrapping cannot even 
start leading to infinitely large tiw and null ratio x_,,/R 1 . For 
intermediate values of F, F',,.<F<F the ratio x_,,/R1 is 
US 8,173,115 B2 
7 
always unit meaning that complete internalization of the par-
ticle occurs, and 0.5ti w grows with F almost linearly. For 
F>F",,,, x_,,/R, decreases, reaches a minimum and then 
increases steadily with increasing E. 
FIG. 3 presents a graph of F_,,,, which is a value of F for a 
fixed R2 corresponding to the minimum for the half-wrapping 
time, as a function of R2 . FIG. 3 also presents a graph of the 
half-wrapping time for F_,, as a function of R 2 . The same date 
is presented in Table 1, together with F' and F",,,. 
TABLE 1 
As the particle size R 2 grows, the aspect ratio F_,,,, for 
which the internalization time is the smallest, reduces from 1 
(R2-R_,,) to 0.3 (R2-500 mu). 
In some cases, the two parameters describing the geometry 
of the elliptical cylindrical particle may be F and R s . 
In such a case, a shape parameter determining a pre-se-
lected cell internalization mode can be an aspect ratio F for a 
particular value of R s . 
The particle with an elliptical cross section can be in a 
"no-endocytosis" mode if the aspect ratio of the particle for a 
particular semilength of a minor axis is less than a first critical 
value F', -(RSK m_)-2/3 , where K m_ is a maximum endocyto-
sis curvature, which is defined below. 
The particle can be in a frustrated endocytosis mode if the 
aspect ratio of the particle for a particular semilength of its 
minor axis is no greater than a second critical value, F " 1= 
(R,K_)213 
The particle can be in an endocytosis mode if the aspect 
ratio of the particle for a particular semilength of its minor 
axis is greater than the first critical value, F' 1 , and less than the 
second critical value, y" 1 . 
FIG. 4 illustrates evolution of the elliptical cylindrical par-
ticle presenting the half-wrapping time 0.5ti w and the wrap-
ping length ratio x m,,/Ri as a function of the aspect ratio F, 
ranging from 0.9 to 4, for R,-50 nun evaluated using a theo-
retical model disclosed in Decuzzi and Ferrari, Biophysical 
Journal, 94, 2008, 3790-3797, which is incorporated herein 
by reference in its entirety. 
Types of Particles 
A type of a particle with a pre-selected internalization 
mode is not particularly limiting. For example, the particle 
may be a liposome, a polymer-based particle, a silicon-and 
silica based particle, a quantum dot, a gold nanoshell, a den-
drimer or a viral particle. 
In some embodiments, particles may be fabricated with a 
shape effective for a pre-selected internalization mode. Yet in 
some embodiments, particles having a shape effective for a 
pre-selected internalization mode may be selected from a 
pool of particles, which may have a broad distribution of 
shapes and/or sizes. The selection from the pool of particles 
may be performed, for example, using Zetasizerrm Nano 
series instrument from Malvern Instruments, Worcestershire, 
United Kingdom, which allows measuring geometrical 
dimensions of the particles. 
8 
Particles may be fabricated using a number of methods. In 
general, fabrication methods that provide a control of the size 
and shape of the particles may be preferred. 
In some embodiments, the particles may be fabricated by 
5 top-down microfabrication or nanofabrication methods, such 
as photolithography, electron beam lithography, X-ray lithog-
raphy, deep UV lithography or nanoprint lithography. The 
advantage of using the top-down fabrication methods can be 
that such methods may provide for a scaled up production of 
10 
particles that are uniform in dimensions. 
The particles may have on their surfaces targeting moieties, 
such as ligands, aptamers or antibodies. For example, ligands 
may be chemically linked to appropriate reactive groups on 
the surface of the particles. Protein ligands may be linked to 
amino- and thiol-reactive groups under conditions effective to 
15 form thioether or amide bonds respectively. Methods for 
attaching antibody or other polymer binding agents to an 
inorganic or polymeric support are detailed, for example, in 
Taylor, R., Ed., Protein Immobilization Fundamentals and 
Applications, pp. 109110 (1991). 
20 	 Non-uniform surface distribution of surface moieties can 
be achieved, for example, when making particles by top-
down microfabrication or nanofabrication methods. For 
example, a substrate, from which the particles are made, may 
be patterned using a coating that resists ligands deposition, so 
25 that the particle has at least two different surface areas: one 
that is resistant to ligand deposition and one that is not. 
Subsequent exposure of the substrate to a solution containing 
a ligand may result in particles having non-uniform distribu-
tion of ligands upon their release from the substrate. 
30 In some embodiments, the particle may have one or more 
channels connecting a reservoir with the surface. In some 
embodiments, the reservoir and the channels may be pores in 
the body of the particle. In such case, the particle may com-
prise a porous or nanoporous material. The pores of the 
35 porous or nanoporous material may be controlled to achieve 
a desired load of the active agent and/or a desired release rate. 
The nanoporous material with controllable pore size may be 
an oxide material, such as S'0 2, Al2O31  or TiO2 . Fabrication 
ofnanoporous oxideparticles, also known as sol gel particles, 
40 is detailed, for example, in Paik J. A. et. al. J. Mater. Res., Vol. 
17, August 2002. The nanoporous material with controllable 
pore size may be also nanoporous silicon. For details of 
fabrication of nanoporous silicon particles, see, for instance, 
Cohen M. H. et. al. Biomedical Microdevices 5:3, 253-259, 
45 2003. 
In some other embodiments, the particle may have no 
channels at all. Such particle may comprise, for example, a 
biodegradable material. For example, the particle may be 
formed of metals, such as iron, titanium, gold, silver, plati- 
50 num, copper, and alloys and oxides thereof. The biodegrad-
able material may be also a biodegradable polymer such as 
polyorthoesters, polyanhydrides, polyamides, polyalkylcy-
anoacrylates, polyphosphazenes, and polyesters. Exemplary 
biodegradable polymers are described, for example, in U.S. 
55 Pat. Nos. 4,933,185, 4,888,176, and 5,010,167. Specific 
examples of such biodegradable polymer materials include 
poly(lactic acid), polyglycolic acid, polycaprolactone, poly-
hydroxybutyrate, poly(N-palmitoyl -trans -4-hydroxy-L-pro-
line ester) and poly(DTH carbonate). 
60 	 In certain embodiments, the particle may be an active agent 
per se. 
Active Agent 
65 The active agent may be a therapeutic compound and/or an 
imaging agent. The selection of a particular active agent 
depends on the desired application. 
Rz, nm Tms„ (0 . 5tw)m;n, see F'_ F"_ 
38.35 (=R_,,,) 1 1 1 
50 0.96 41.60 0.87 1.30 
75 0.80 78.33 0.71 1.95 
100 0.68 123.4 0.62 2.61 
150 0.56 243.7 0.50 3.91 
300 0.40 823.6 0.36 7.82 
500 0.32 2105.2 0.28 13.0 
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The therapeutic agent may be a physiologically or pharma- 	 Novembiehin, Phenesterine, Prednimustine, Trofosfamide, 
cologically active substance that can produce a desired bio- 	 uracil mustard; nitroureas, such as Cannustine, Chlorozoto- 
logical effect in fenestrated vasculature of the subject, such as 	 cin, Fotemustine, Lomustine, Nimustine, and Ranimustine; 
a mammal or a human. The therapeutic agent may be an 	 antibiotics, such as Aclacinomysins, Actinomycin, Authra- 
inorganic or organic compound, including peptides, proteins, 5 mycin, Azaserine, Bleomycins, Cactinomycin, Calicheami- 
nucleic acids, and small molecules. The therapeutic agent 	 cin, Carabicin, Canninomycin, Carzinophilin, Chromoiny- 
may be in various forms, such as an unchanged molecule, 	 cins, Dactinomycin, Daunorubicin, Detorubicin, 6-diazo-5- 
molecular complex, pharmacologically acceptable salt, such 	 oxo-L-norleucine, Doxorubicin, Epirubicin, Esorubicin, 
as hydrochloride, hydrobromide, sulfate, laurate, palmitate, 	 Idambicin, Marcellomycin, Mitomycins, mycophenolic acid, 
phosphate, nitrite, nitrate, borate, acetate, maleate, tartrate, io Nogalamycin, Olivomycins, Peplomycin, Potfiromycin, 
oleate, salicylate, andthe like. For an acidic therapeutic agent, 	 Puromycin, Quelamycin, Rodorubicin, Streptonigrin, Strep- 
salts of metals, amines or organic cations, for example, qua- 	 tozocin, Tubercidin, Ubenimex, Zinostatin, and Zorubicin; 
ternary ammonium, may be used. Derivatives of drugs, such 	 anti-metabolites such as Methotrexate and 5-fluorouracil 
as bases, esters and amides also may be used as a therapeutic 	 (5-FU); folic acid analogues, such as Denopterin, Methotrex- 
agent. A therapeutic agent that is water insoluble may be used 15 ate, Pteropterin, and Trimetrexate; purine analogs, such as 
in a form that is a water soluble derivative thereof, or as a base 	 Fludarabine, 6-mercaptopurine, Thiamiprine, and Thiogua- 
derivative thereof, which in either instance, or by its delivery, 	 nine; pyrimidine analogs, such as Ancitabine, Azacitidine, 
is converted by enzymes, hydrolyzed by the body pH, or by 	 6-azauridine, Cannofur, Cytarabine, Dideoxyuridine, Doxi- 
other metabolic processes to the original therapeutically 	 fluridine, Enocitabine, Floxuridine, and 5-FU; androgens, 
active form. 	 20 such as Calusterone, Dromostanolone Propionate, Epi- 
The therapeutic agent may be a chemotherapeutic agent, an 	 tiostanol, Rnepitiostane, and Testolactone; anti-adrenals, 
immuno suppressive agent, a cytokine, a cytotoxic agent, a 	 such as aminoglutethimide, Mitotane, and Trilostane; folic 
nucleolytic compound, a radioactive isotope, a receptor, and 	 acid replenisher, such as frolinic acid; aceglatone; aldophos- 
a pro-drug activating enzyme, which may be naturally occur- 	 phamide glycoside; aminolevulinic acid; Amsacrine; 
ring or produced by synthetic or recombinant methods, or any 25 Bestrabucil; Bisantrene; Edatraxate; Defofamine; Demecol- 
combination thereof. 	 cine; Diaziquone; Elfornithine; elliptinium acetate; Etoglu- 
Drugs that are affected by classical multidrug resistance, 	 cid; gallium nitrate; hydroxyurea; Lentinan; Lonidamine; 
such as vinca alkaloids (e.g., vnblastine and vincristine), the 	 Mitoguazone; Mitoxantrone; Mopidamol; Nitracrine; Pen- 
anthracyclines (e.g., doxorubicin and daunorubicin), RNA 	 tostatin; Phenamet; Pirarubicin; podophyllinic acid; 2-ethyl- 
transcription inhibitors (e.g., actinomycin-D) and microtu-  3o hydrazide; Procarbazine; PSKO; Razoxane; Sizofrran; 
bule stabilizing drugs (e.g., paclitaxel) may have a particular 	 Spirogermanium; tenuazonic acid; triaziquone; 2,2',2"- 
utility as the therapeutic agent. 	 trichlorotriethylamine; Urethan; Vindesine; Dacarbazine; 
A cancer chemotherapy agent can be also a preferred thera- 	 Mannomustine; Mitobronitol; Mitolactol; Pipobroman; 
peutic agent. Useful cancer chemotherapy drugs include 	 Gacytosine; Arabinoside (`Ara-C"); cyclophosphamide; 
nitrogen mustards, nitrosorueas, ethyleneimine, alkane sul-  35 thiotEPa; taxoids, e.g., Paclitaxel (TAXOLO, Bristol-Myers 
fonates, tetrazine, platinum compounds, pyrimidine analogs, 	 Squibb Oncology, Princeton, N.7.) and Doxetaxel (TAXO- 
purine analogs, antimetabolites, folate analogs, anthracy- 	 TEREO, Rhone-Poulenc Rorer, Antony, France); Chloram- 
clines, taxanes, vinca alkaloids, topoisomerase inhibitors and 
	
bucil; Gemcitabine; 6-thioguanine; Mercaptopurine; Meth- 
hormonal agents. Exemplary chemotherapy drugs are Acti- 	 otrexate; platinum analogs, such as Cisplatin and 
nomycin-D, Alkeran, Ara-C, Anastrozole, Asparaginase, 40 Carboplatin; Vinblastine; platinum; etoposide (VP-16); Ifos- 
BiCNU, Bicalutamide, Bleomycin, Busulfan, Capecitabine, 	 famide; Mitomycin C; Mitoxantrone; Vincristine; Vinorel- 
Carboplatin, Carboplatinum, Carmustine, CCNU, Chloram- 	 bine; Navelbine; Novantrone; Teniposide; Daunomycin; 
bucil, Cisplatin, Cladribine, CPT-11, Cyclophosphamide, 	 Aminopterin; Xeloda; Ibandronate; CPT-11; topoisomerase 
Cytarabine, Cytosine arabinoside, Cytoxan, Dacarbazine, 	 inhibitor RFS 2000; difluoromethylornithine (DMFO); ret- 
Dactinomycin, Daunorubicin, Dexrazoxane, Docetaxel, 45 inoic acid; Esperamicins; Capecitabine; and phannaceuti- 
Doxorubicin, DTIC, Epirubicin, Ethyleneimine, Etoposide, 	 cally acceptable salts, acids or derivatives of any of the above. 
Floxuridine, Fludarabine, Fluorouracil, Flutamide, Fotemus- 	 Also included are anti-hormonal agents that act to regulate or 
tine, Gemcitabine, Herceptin, Hexamethylamine, Hydrox- 	 inhibit hormone action on tumors, such as anti-estrogens 
yurea, Idarubicin, Ifosfamide, Irinotecan, Lomustine, 	 including for example Tamoxifen, Raloxifene, aromatase 
Mechlorethamine, Melphalan, Mercaptopurine, Methotrex-  50 inhibiting 4(5)-imidazoles, 4 Hydroxytamoxifen, Trioxifene, 
ate, Mitomycin, Mitotane, Mitoxantrone, Oxaliplatin, Pacli- 	 Keoxifene, Onapristone, And Toremifene (Fareston); and 
taxel, Pamidronate, Pentostatin, Plicamycin, Procarbazine, 	 anti-androgens such as Flutamide, Nilutamide, Bicalutamide, 
Rituximab, Steroids, Streptozocin, STI-571, Streptozocin, 	 Leuprolide, and Goserelin; and pharmaceutically acceptable 
Tamoxifen, Temozolomide, Teniposide, Tetrazine, Thiogua- 	 salts, acids or derivatives of any of the above. 
nine, Thiotepa, Tomudex, Topotecan, Treosulphan, Trimetr-  55 	 Cytokines may be also used as the therapeutic agent. 
exate, Vinblastine, Vincristine, Vindesine, Vinorelbine, 	 Examples of such cytokines are lymphokines, monokines, 
VP-16, and Xeloda. 	 and traditional polypeptide hormones. Included among the 
Useful cancer chemotherapy drugs also include alkylating 	 cytokines are growth hormones, such as human growth hor- 
agents, such as Thiotepa and cyclosphosphamide; alkyl sul- 	 mone, N-methionyl human growth hormone, and bovine 
fonates, such as Busulfan, Improsulfan and Piposulfan; aziri-  60 growth hormone; parathyroid hormone; thyroxine; insulin; 
dines, such as Benzodopa, Carboquone, Meturedopa, and 	 proinsulin; relaxin; prorelaxin; glycoprotein hormones, such 
Uredopa; ethylenimines and methylamelamines, including 	 as follicle stimulating hormone (FSH), thyroid stimulating 
altretamine, triethylenemelamine, trietylenephosphoramide, 	 hormone (TSH), and luteinizing hormone (LH); hepatic 
triethylenethiophosphaoramide and trimethylolomelamine; 	 growth factor; fibroblast growth factor; prolactin; placental 
nitrogen mustards, such as Chlorambucil, Chlornaphazine, 65 lactogen; tumor necrosis factor-a and -(3; mullerian-inhibit- 
Cholophosphamide, Estramustine, Ifosfamide, mechlore- 	 ing substance; mouse gonadotropin-associated peptide; 
thamine, mechlorethamine oxide hydrochloride, Melphalan, 	 inhibin; activin; vascular endothelial growth factor; integrin; 
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thrombopoietin (TPO); nerve growth factors, such as NGF-(3; 	 not heat-stable material may be sterilized by passage through 
platelet growth factor; transforming growth factors (TGFs), 	 a commercially-available sterilization filter. Of course, filtra- 
such as TGF-a and TGF-(3; insulin-like growth factor-I and 	 tion may be used only in cases where the particles is smaller 
-II; erythropoietin (EPO); osteoinductive factors; interferons 	 than the pores of the sterilizing filter. 
such as interferon-a, -(3 and -y; colony stimulating factors 5 	 The particles may be administered to a subject in need of 
(CSFs), such as macrophage-CSF (M-CSF); granulocyte- 	 therapeutic intervention via a number of suitable administra- 
macrophage-CSF (GM-CSF); and granulocyte-CSF (GCSF); 	 tion methods. The particular method employed for a specific 
interleukins (ILs), such as IL-1, IL-I a, IL-2, IL-3, IL-4, IL-5, 	 application can be determined by the attending physician. For 
IL-6, IL-7, IL-8, IL-9, IL-I1, IL-12, IL-15; a tumor necrosis 	 example, the particles may be administered by one of the 
factor, such as TNF-a or TNF-(3; and other polypeptide fac-  io following routes: topical, parenteral, inhalation, oral, vaginal 
tors including LIE and kit ligand (KL). As used herein, the 	 and anal. Intravascular administration, which includes intra- 
tern cytokine includes proteins from natural sources or from 	 venous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) 
recombinant cell culture and biologically active equivalents 	 injection, may be particularly preferred. 
of the native sequence cytokines. 	 Intravascular administration may be either local or sys- 
The imaging agent may be a substance, that can provide 15 temic. Local intravascular delivery may be used to bring the 
imaging information about a targeted site in a body of an 	 particles in the vicinity of a body site having a known tumor 
animal, such as a mammal or a human being. The imaging 	 or inflammation by use of guided catheter system, such as a 
agent can comprise magnetic material, such as iron oxide, for 	 CAT-scan guided catheter. General injection, such as a bolus 
magnetic resonance imaging. For optical imaging, the active 	 i.v. injection or continuous/trickle-feed i.v. infusion are typi- 
agent can be, for example, a semiconductor nanocrystal or 20 cally systemic. 
quantum dot. For optical coherence tomography imaging, the 	 The particles may be injected into the blood stream and 
imaging agent can be a metal, e.g. gold or silver, nanocage 	 allowed to circulate and localize to their target site. Prefer- 
particle. The imaging agent can be also an ultrasound contrast 	 ably, the particles are injected to a vasculature of the target 
agent, such as a micro or nanobubble or iron oxide micro or 	 site. 
nanoparticle. 	 25 	
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bohydrates including glucose or dextrans, chelating agents 	 What is claimed is: 
such as EDTA, or other excipients. 	 1. A method of formulating a particle composition having 
Prior to administration to the subject, the suspension of 	 a preselected cell internalization mode, comprising: 
particles may be sterilized by a suitable sterilization method. 65 	 a) selecting a cell having surface receptors; and 
Particles fabricated from a heat-stable material may be heat- 	 b) fabricating ellipsoidal particles that have i) surface moi- 
sterilized, e.g., using an autoclave. Particles fabricated from a 	 eties that have an affinity for or are capable of binding to 
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the receptors, and ii) an aspect ratio that is effective for 
the preselected cell internalization mode for the selected 
cell, wherein the pre-selected internalization mode is 
selected from a full endocytosis, a frustrated endocytosis 
and no endocytosis. 
2. The method of claim 1, wherein the cell is an endothelial 
cell. 
3. The method of claim 2, wherein the endothelial cell is an 
endothelial vasculature cell. 
4. The method of claim 3, wherein the receptors are angio-
genesis vasculature receptors, coopted vasculature receptors 
or renormalized receptors. 
5. The method of claim 1, wherein the cell is a non-phago-
cyte cell. 
6. The method of claim 1, wherein the surface moieties are 
ligands that are capable of binding to the receptors. 
14 
7. The method of claim 1, wherein the fabricating com-
prises fabricating by a top-down process. 
8. The method of claim 1, wherein the fabricating com- 
prises disposing the moieties onto a surface of the particles. 
5 	 9. The method of claim 1, wherein the obtaining comprises 
selecting the particles from a particle population. 
10. The method of claim 1, wherein the particles comprise 
an active agent. 
11. The method of claim 10, wherein the active agent 
io comprises an imaging agent or a therapeutic agent. 
12. The method of claim 1, wherein said particles are 
nanoparticles. 
13. The method of claim 1, further comprising determining 
the aspect ratio based on a surface density of the surface 
15 moieties and a surface density of the surface receptors. 
